LAT4 drives temozolomide induced radiotherapy resistance in glioblastoma by enhancing mTOR pathway activation

Related articles

1. PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomide

   This article has 22 authors:

   1. Shumpei Onishi
   2. Sridharan Jayamohan
   3. Ashis Chowdhury
   4. Sarah Rivas
   5. Yoshihiro Otani
   6. Sara A. Murphy
   7. Kimberly A. Rivera-Caraballo
   8. Stuart Walbridge
   9. Ashish H. Shah
   10. Bayu Sisay
   11. Dragan Maric
   12. Abdel Elkahloun
   13. Kory Johnson
   14. John Heiss
   15. Tae Jin Lee
   16. Sangamesh G. Kumbar
   17. Desmond A. Brown
   18. Ji Young Yoo
   19. Andrew Brenner
   20. Balveen Kaur
   21. Gangadhara R. Sareddy
   22. Yeshavanth Kumar Banasavadi-Siddegowda

2. Proinflammatory macrophage-derived medium enhances temozolomide sensitivity in glioblastoma via pSTAT3-mediated downregulation of DNA repair enzymes

   This article has 10 authors:

   1. Susana López-López
   2. Beatriz Castro-Robles
   3. María José M. Díaz‐Guerra
   4. Lourdes Arias-Salazar
   5. Hernán Sandoval
   6. Daniel García-Pérez
   7. Christoph J. Klein-Zampaña
   8. Rosa A Barbella-Aponte
   9. Tomás Segura
   10. Gemma Serrano-Heras

3. FGFR1 inhibition improves therapy efficacy and prevents metabolic adaptation associated with temozolomide resistance in glioblastoma

   This article has 16 authors:

   1. Laura Zarzuela
   2. Ignacio G. López-Cepero
   3. Kevin M. Rattigan
   4. Elena Sánchez-Escabias
   5. Macarena Morillo-Huesca
   6. Ana Reina-Bando
   7. Sara S. Oltra
   8. Jesús M. Sierra-Párraga
   9. María Ceballos-Chávez
   10. Vivian Capilla-González
   11. Gema Moreno-Bueno
   12. Piedad del Socorro Murdoch
   13. José C. Reyes
   14. G. Vignir Helgason
   15. Mercedes Tomé
   16. Raúl V. Durán